David Sallman, MD, Moffitt Cancer Center, Tampa, FL, emphasizes the importance of including patients with myelodysplastic syndromes (MDS) in trials evaluating therapies for acute myeloid leukemia (AML), explaining that MDS cells express many of the targets utilized for AML therapies. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.